Call:
+44 (0) 1865 784074
Oxford Vacmedix UK Limited:
Oxford, UK, OX4 4GA
Email:
enquiries@oxfordvacmedix.com
- Seeking Series B investment for next phase of clinical trials
Call:
+44 (0) 1865 784074
Oxford Vacmedix UK Limited:
Oxford, UK, OX4 4GA
Email:
enquiries@oxfordvacmedix.com
Company News
Chicago, USA - May & June 2026 Introduction Professor Shisong Jiang, Chief Scientific Officer, and Dr Nam Park, Chief Business Officer, represented Oxford Vacm
The American Society of Clinical Oncology (ASCO) has accepted the Phase 1b dose expansion part of the OVM-200 Phase 1 trial for presentation at its annual meeting.
The OVM-200 Phase 1 trial has met both primary and secondary endpoints and additionally early observations of clinical efficacy have been seen. Oxford, UK – 21st
The initial part of the Phase I trial of OVM-200, Oxford Vacmedix’s lead cancer immunotherapy has been published in eClinical Medicine, a journal of the Lancet gro
All patients have completed treatment in the Phase 1 trial of Oxford Vacmedix’s lead cancer vaccine OVM-200 Oxford, UK – 17 November 2025 Press Release - Las
The Phase 1 trial of OVM-200, Oxford Vacmedix’s lead cancer vaccine, has been fully recruited in only three months since the new extended dosing protocol was imple
Contact Us
If you have any questions or want to get in touch, please contact our team.
(c) 2025 Oxford Vacmedix UK Limited | Company Registration: 07994205
English